________________________________________________________
____Explicit____
134..136
0,1,1,1,1,1,1,5,0
#### Text ####
as
##############
#### Features ####
Wr, Comm, Null, Null
as, Contingency.Cause.Reason
____Arg1____
9..132
0,0;0,1,0;0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0;0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2;0,1,1,1,1,1,1,3;0,1,1,1,1,1,1,4;0,2
#### Text ####
Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
137..211
0,1,1,1,1,1,1,5,1
#### Text ####
companies with newer, big-selling prescription drugs fared especially well
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
250..257
1,2
#### Text ####
however
##############
#### Features ####
Wr, Comm, Null, Null
however, Comparison.Contrast
____Arg1____
9..132
0,0;0,1,0;0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0;0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2;0,1,1,1,1,1,1,3;0,1,1,1,1,1,1,4;0,2
#### Text ####
Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
215..248;259..385
1,0;1,1;1,3;1,4;1,5;1,6
#### Text ####
For the third consecutive quarter most of the companies' revenues were battered by adverse foreign-currency translations as a result of the strong dollar abroad
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
620
3
#### Features ####
Wr, Comm, Null, Null
while, Comparison.Contrast.Juxtaposition
____Arg1____
403..618
2,1,1
#### Text ####
that Merck & Co., Eli Lilly & Co., Warner-Lambert Co. and the Squibb Corp. unit of Bristol-Myers Squibb Co. all benefited from strong sales of relatively new, higher-priced medicines that provide wide profit margins
##############
#### Features ####
Ot, Comm, Null, Null
389..402
2,0;2,1,0;2,2
#### Text ####
Analysts said
##############
____Arg2____
620..803
3
#### Text ####
Less robust earnings at Pfizer Inc. and Upjohn Co. were attributed to those companies' older products, many of which face stiffening competition from generic drugs and other medicines
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
1057..1068
5,0,0
#### Text ####
As a result
##############
#### Features ####
Ot, Comm, Null, Null
1166..1183
5,1;5,2;5,3;5,4;5,5
#### Text ####
Mr. Riccardo said
##############
as a result, Contingency.Cause.Result
____Sup1____
987..1055
4,1,1,1,2,1,2,1,2
#### Text ####
such as consolidating manufacturing plants and administrative staffs
##############
____Arg1____
866..985
4,1,1,0;4,1,1,1,0;4,1,1,1,1;4,1,1,1,2,0;4,1,1,1,2,1,0;4,1,1,1,2,1,1;4,1,1,1,2,1,2,0;4,1,1,1,2,1,2,1,0;4,1,1,1,2,1,2,1,1
#### Text ####
that over the past few years most drug makers have shed their slow-growing businesses and instituted other cost savings
##############
#### Features ####
Ot, Comm, Null, Null
807..865
4,0;4,1,0;4,2
#### Text ####
Joseph Riccardo, an analyst with Bear, Stearns & Co., said
##############
____Arg2____
1071..1163
5,0,1;5,0,2;5,0,3;5,0,4
#### Text ####
major new products are having significant impact, even on a company with very large revenues
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1307
7
#### Features ####
Wr, Comm, Null, Null
in fact, Expansion.Restatement.Specification
____Arg1____
1201..1305
6,1,1
#### Text ####
profit for the dozen or so big drug makers, as a group, is estimated to have climbed between 11% and 14%
##############
#### Features ####
Ot, Comm, Null, Null
1187..1200
6,0;6,1,0;6,2
#### Text ####
Analysts said
##############
____Arg2____
1307..1335;1388..1499
7,0;7,3,1
#### Text ####
While that's not spectacular that the rate of growth will "look especially good as compared to other companies if the economy turns downward
##############
#### Features ####
Ot, Comm, Null, Null
1337..1387
7,1;7,2;7,3,0;7,4;7,5
#### Text ####
Neil Sweig, an analyst with Prudential Bache, said
##############
________________________________________________________
________________________________________________________
____Explicit____
1307..1312
7,0,0
#### Text ####
While
##############
#### Features ####
Wr, Comm, Null, Null
while, Comparison.Contrast
____Arg1____
1388..1499
7,3,1
#### Text ####
that the rate of growth will "look especially good as compared to other companies if the economy turns downward
##############
#### Features ####
Ot, Comm, Null, Null
1337..1387
7,1;7,2;7,3,0;7,4;7,5
#### Text ####
Neil Sweig, an analyst with Prudential Bache, said
##############
____Arg2____
1313..1335
7,0,1
#### Text ####
that's not spectacular
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
1470..1472
7,3,1,1,1,2,2,0
#### Text ####
if
##############
#### Features ####
Ot, Comm, Null, Null
1337..1387
7,1;7,2;7,3,0;7,4;7,5
#### Text ####
Neil Sweig, an analyst with Prudential Bache, said
##############
if, Contingency.Condition.Hypothetical
____Arg1____
1388..1469
7,3,1,0;7,3,1,1,0;7,3,1,1,1,0;7,3,1,1,1,1;7,3,1,1,1,2,0;7,3,1,1,1,2,1
#### Text ####
that the rate of growth will "look especially good as compared to other companies
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1473..1499
7,3,1,1,1,2,2,1
#### Text ####
the economy turns downward
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1799
9
#### Features ####
Wr, Comm, Null, Null
in fact, Expansion.Restatement.Specification
____Arg1____
1524..1647
8,1,1,0;8,1,1,1,0;8,1,1,1,1,0;8,1,1,1,1,1;8,1,1,1,1,2;8,1,1,1,1,3,0;8,1,1,1,1,3,1,0;8,1,1,1,1,3,1,1;8,1,1,1,1,3,1,2,0;8,1,1,1,1,3,1,2,1,0;8,1,1,1,1,3,1,2,1,1,0;8,1,1,1,1,3,1,2,1,1,1,0;8,1,1,1,1,3,1,2,1,1,1,1,0;8,1,1,1,1,3,1,2,1,1,1,1,1,0;8,1,1,1,1,3,1,2,1,1,1,1,1,1
#### Text ####
that Merck's profit for the quarter rose by about 22%, propelled by sales of its line-up of fast-growing prescription drugs
##############
#### Features ####
Ot, Comm, Null, Null
1504..1523
8,0;8,1,0;8,2
#### Text ####
Mr. Sweig estimated
##############
____Arg2____
1799..1921
9,0
#### Text ####
Profit climbed even though Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar
##############
#### Features ####
Ot, Comm, Null, Null
1923..1937
9,1;9,2;9,3;9,4
#### Text ####
Mr. Sweig said
##############
________________________________________________________
________________________________________________________
____Explicit____
1814..1825
9,0,1,1,0;9,0,1,1,1
#### Text ####
even though
##############
#### Features ####
Ot, Comm, Null, Null
1923..1937
9,1;9,2;9,3;9,4
#### Text ####
Mr. Sweig said
##############
though, Comparison.Concession.Expectation
____Arg1____
1799..1813
9,0,0;9,0,1,0
#### Text ####
Profit climbed
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1826..1921
9,0,1,1,2
#### Text ####
Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1939
10
#### Features ####
Wr, Comm, Null, Null
in fact, Expansion.Restatement.Specification
____Arg1____
1799..1921
9,0
#### Text ####
Profit climbed even though Merck's sales were reduced by "one to three percentage points" as a result of the strong dollar
##############
#### Features ####
Ot, Comm, Null, Null
1923..1937
9,1;9,2;9,3;9,4
#### Text ####
Mr. Sweig said
##############
____Arg2____
1939..2017
10
#### Text ####
In the third quarter of 1988, Merck earned $311.8 million, or 79 cents a share
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
2264
13
#### Features ####
Wr, Comm, Null, Null
in fact, Expansion.Restatement.Specification
____Arg1____
2138..2262
12,1,1,1,1,1
#### Text ####
that Lilly's earnings for the quarter jumped about 20%, largely because of the performance of its new anti-depressant Prozac
##############
#### Features ####
Ot, PAtt, Null, Null
2125..2137
12,1,1,0;12,1,1,1,0;12,1,1,1,1,0
#### Text ####
he estimated
##############
____Arg2____
2264..2357
13
#### Text ####
The drug, introduced last year, is expected to generate sales of about $300 million this year
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
2360
14
#### Features ####
Wr, Comm, Null, Null
in other words, Expansion.Restatement.Generalization
____Arg1____
2264..2357
13
#### Text ####
The drug, introduced last year, is expected to generate sales of about $300 million this year
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2360..2401
14,1
#### Text ####
It's turning out to be a real blockbuster
##############
#### Features ####
Ot, Comm, Null, Null
2404..2418
14,0;14,2;14,3;14,4;14,5;14,6
#### Text ####
Mr. Sweig said
##############
________________________________________________________
________________________________________________________
____EntRel____
2499
16
____Arg1____
2422..2497
15
#### Text ####
In last year's third quarter, Lilly earned $171.4 million, or $1.20 a share
##############
____Arg2____
2499..2538
16
#### Text ####
In Indianapolis, Lilly declined comment
##############
________________________________________________________
________________________________________________________
____Explicit____
2602..2606
17,1,1,1,1,1,1
#### Text ####
also
##############
#### Features ####
Wr, Comm, Null, Null
also, Expansion.Conjunction
____Arg1____
2125..2262
12,1,1
#### Text ####
he estimated that Lilly's earnings for the quarter jumped about 20%, largely because of the performance of its new anti-depressant Prozac
##############
#### Features ####
Ot, Comm, Null, Null
2110..2124
12,0;12,1,0;12,2
#### Text ####
Mr. Sweig said
##############
____Arg2____
2564..2601;2607..2714
17,1,1,0;17,1,1,1,0;17,1,1,1,1,0;17,1,1,1,1,1,0;17,1,1,1,1,1,2
#### Text ####
they expected Warner-Lambert's profit to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year
##############
#### Features ####
Ot, Comm, Null, Null
2542..2563
17,0;17,1,0;17,2
#### Text ####
Several analysts said
##############
________________________________________________________
________________________________________________________
____EntRel____
2716
18
____Arg1____
2542..2714
17
#### Text ####
Several analysts said they expected Warner-Lambert's profit also to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year
##############
____Arg2____
2716..2853
18
#### Text ####
The company is praised by analysts for sharply lowering its costs in recent years and shedding numerous companies with low profit margins
##############
________________________________________________________
________________________________________________________
____Implicit____
2855
19
#### Features ####
Wr, Comm, Null, Null
because, Contingency.Cause.Reason
____Arg1____
2716..2853
18
#### Text ####
The company is praised by analysts for sharply lowering its costs in recent years and shedding numerous companies with low profit margins
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2855..2883;2900..2985
19,0;19,2;19,3
#### Text ####
The company's lean operation allowed sharp-rising sales from its cholesterol drug, Lopid, to power earnings growth
##############
#### Features ####
Ot, Comm, Null, Null
2885..2898
19,1
#### Text ####
analysts said
##############
________________________________________________________
________________________________________________________
____Implicit____
2987
20
#### Features ####
Wr, Comm, Null, Null
as, Contingency.Cause.Reason
____Arg1____
2855..2883;2900..2985
19,0;19,2;19,3
#### Text ####
The company's lean operation allowed sharp-rising sales from its cholesterol drug, Lopid, to power earnings growth
##############
#### Features ####
Ot, Comm, Null, Null
2885..2898
19,1
#### Text ####
analysts said
##############
____Arg2____
2987..3076
20
#### Text ####
Lopid sales are expected to be about $300 million this year, up from $190 million in 1988
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
3078
21
#### Features ####
Wr, Comm, Null, Null
indeed, Expansion.Conjunction
____Arg1____
2987..3076
20
#### Text ####
Lopid sales are expected to be about $300 million this year, up from $190 million in 1988
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3078..3181
21
#### Text ####
In Morris Plains, N.J., a spokesman for the company said the analysts' projections are "in the ballpark
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
3443
23
____Arg1____
3186..3441
22
#### Text ####
Squibb's profit, estimated by analysts to be about 18% above the $123 million, or $1.25 a share, it earned in the third quarter of 1988, was the result of especially strong sales of its Capoten drug for treating high blood pressure and other heart disease
##############
____Arg2____
3443..3518
23
#### Text ####
The company was officially merged with Bristol-Myers Co. earlier this month
##############
________________________________________________________
________________________________________________________
____EntRel____
3520
24
____Arg1____
3443..3518
23
#### Text ####
The company was officially merged with Bristol-Myers Co. earlier this month
##############
____Arg2____
3520..3553
24
#### Text ####
Bristol-Myers declined to comment
##############
________________________________________________________
________________________________________________________
____Explicit____
3726..3741
25,1,1,1,1,1,0;25,1,1,1,1,1,1
#### Text ####
largely because
##############
#### Features ####
Ot, Comm, Null, Null
3557..3590
25,0;25,1,0;25,2;25,3
#### Text ####
Mr. Riccardo of Bear Stearns said
##############
because, Contingency.Cause.Reason
____Arg1____
3591..3725
25,1,1,0;25,1,1,1,0;25,1,1,1,1,0
#### Text ####
that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3743..3782
25,1,1,1,1,1,3
#### Text ####
those companies are really managed well
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
3785
26
____Arg1____
3557..3782
25
#### Text ####
Mr. Riccardo of Bear Stearns said that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are largely because "those companies are really managed well
##############
____Arg2____
3785..3940
26
#### Text ####
ScheringPlough earned $94.4 million, or 84 cents a share, while Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier
##############
________________________________________________________
________________________________________________________
____Explicit____
3843..3848
26,1,3,0
#### Text ####
while
##############
#### Features ####
Wr, Comm, Null, Null
while, Comparison.Contrast.Juxtaposition
____Arg1____
3785..3841
26,0;26,1,0;26,1,1;26,1,2;26,2
#### Text ####
ScheringPlough earned $94.4 million, or 84 cents a share
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3849..3940
26,1,3,1
#### Text ####
Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
4133
28
#### Features ####
Wr, Comm, Null, Null
also, Expansion.Conjunction
____Arg1____
3999..4131
27,3,1
#### Text ####
the company has "no problems" with the average estimate by a analysts that third-quarter earnings per share rose by about 19%, to $1
##############
#### Features ####
Ot, Comm, Null, Null
3944..3998
27,0;27,1;27,2;27,3,0;27,4
#### Text ####
In Madison, N.J., a spokesman for Schering-Plough said
##############
____Arg2____
4133..4212
28,0,0;28,0,1,0;28,0,1,1,0;28,0,1,1,1,0;28,0,1,1,1,1,0;28,0,1,1,1,1,1;28,0,1,1,1,1,2
#### Text ####
The company expects to achieve the 20% increase in full-year earnings per share
##############
#### Features ####
Ot, Comm, Null, Null
4245..4263
28,1;28,2;28,3;28,4
#### Text ####
the spokesman said
##############
________________________________________________________
________________________________________________________
____Explicit____
4267..4276
29,0
#### Text ####
Meanwhile
##############
#### Features ####
Wr, Comm, Null, Null
meanwhile, Comparison.Contrast.Juxtaposition
____Arg1____
1524..1577;2138..2192;2578..2714;3225..3321;3591..3721;3661..3721
8,1,1,0;8,1,1,1,0;8,1,1,1,1,0;8,1,1,1,1,1;8,1,1,1,1,2;12,1,1,1,1,1,0;12,1,1,1,1,1,1,0;12,1,1,1,1,1,1,1,0;12,1,1,1,1,1,1,1,1;12,1,1,1,1,1,1,1,2;17,1,1,1,1,1;22,2,1,2;25,1,1,0;25,1,1,1,0;25,1,1,1,0,2;25,1,1,1,0,3
#### Text ####
that Merck's profit for the quarter rose by about 22% that Lilly's earnings for the quarter jumped about 20% Warner-Lambert's profit also to increase by more than 20% from $87.7 million, or $1.25 a share, it reported in the like period last year to be about 18% above the $123 million, or $1.25 a share, it earned in the third quarter of 1988 that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% , and Bristol-Meyers's expected profit increase of about 13%
##############
#### Features ####
Ot, Ctrl, Null, Null
3203..3224;3557..3590
22,2,0;22,2,1,0;22,2,1,1;25,0;25,1,0;25,2;25,3
#### Text ####
estimated by analysts Mr. Riccardo of Bear Stearns said
##############
____Arg2____
4404..4426
29,3,1,1,1,2,1,1,1,1
#### Text ####
to decline by about 5%
##############
#### Features ####
Ot, Ctrl, Null, Null
4366..4403
29,3,1,1,1,2,1,0;29,3,1,1,1,2,1,1,0;29,3,1,1,1,2,1,1,1,0
#### Text ####
earnings in the quarter were expected
##############
________________________________________________________
________________________________________________________
____Explicit____
4363..4365
29,3,1,1,1,2,0
#### Text ####
as
##############
#### Features ####
Ot, Comm, Null, Null
4278..4291
29,1;29,2;29,3,0;29,4
#### Text ####
analysts said
##############
as, Contingency.Pragmatic cause.Justification
____Arg1____
4267..4276;4292..4361
29,0;29,1;29,3,1,0;29,3,1,1,0;29,3,1,1,1,0;29,3,1,1,1,1;29,4
#### Text ####
Meanwhile Pfizer's recent string of lackluster quarterly performances continued
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
4366..4426
29,3,1,1,1,2,1
#### Text ####
earnings in the quarter were expected to decline by about 5%
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
4428
30
#### Features ####
Wr, Comm, Null, Null
in particular, Expansion.Restatement.Specification
____Arg1____
4292..4426
29,3,1
#### Text ####
Pfizer's recent string of lackluster quarterly performances continued, as earnings in the quarter were expected to decline by about 5%
##############
#### Features ####
Ot, Comm, Null, Null
4278..4291
29,1;29,2;29,3,0;29,4
#### Text ####
analysts said
##############
____Arg2____
4428..4572
30
#### Text ####
Sales of Pfizer's important drugs, Feldene for treating arthritis, and Procardia, a heart medicine, have shrunk because of increased competition
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____AltLex____
4614..4617
31,1,1,4
#### Text ####
too
##############
#### Features ####
Wr, Comm, Null, Null
Expansion.Conjunction
____Arg1____
4428..4572
30
#### Text ####
Sales of Pfizer's important drugs, Feldene for treating arthritis, and Procardia, a heart medicine, have shrunk because of increased competition
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
4575..4617
31,1
#### Text ####
The (strong) dollar hurt Pfizer a lot, too
##############
#### Features ####
Ot, Comm, Null, Null
4620..4634
31,0;31,2;31,3;31,4;31,5;31,6
#### Text ####
Mr. Sweig said
##############
________________________________________________________
________________________________________________________
____EntRel____
4636
32
____Arg1____
4575..4634
31
#### Text ####
The (strong) dollar hurt Pfizer a lot, too," Mr. Sweig said
##############
____Arg2____
4636..4714
32
#### Text ####
In the third quarter last year, Pfizer earned $216.8 million, or $1.29 a share
##############
________________________________________________________
________________________________________________________
____EntRel____
4716
33
____Arg1____
4636..4714
32
#### Text ####
In the third quarter last year, Pfizer earned $216.8 million, or $1.29 a share
##############
____Arg2____
4716..4757
33
#### Text ####
In New York, the company declined comment
##############
________________________________________________________
________________________________________________________
____EntRel____
4922
35
____Arg1____
4761..4920
34
#### Text ####
Analysts said they expected Upjohn's profit to be flat or rise by only about 2% to 4% as compared with $89.6 million, or 49 cents a share, it earned a year ago
##############
____Arg2____
4922..5003
35
#### Text ####
Upjohn's biggest-selling drugs are Xanax, a tranquilizer, and Halcion, a sedative
##############
________________________________________________________
________________________________________________________
____Explicit____
5185..5189
37,0,0
#### Text ####
Also
##############
#### Features ####
Wr, Comm, Null, Null
also, Expansion.Conjunction
____Arg1____
5007..5183
36
#### Text ####
Sales of both drugs have been hurt by new state laws restricting the prescriptions of certain tranquilizing medicines and adverse publicity about the excessive use of the drugs
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
5191..5412
37,0,1;37,0,2;37,0,3;37,0,4;37,0,5
#### Text ####
the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year, but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising
##############
#### Features ####
Ot, Comm, Null, Null
5414..5427
37,1;37,2;37,3;37,4
#### Text ####
analysts said
##############
________________________________________________________
________________________________________________________
____Explicit____
5288..5291
37,0,4
#### Text ####
but
##############
#### Features ####
Ot, Comm, Null, Null
5414..5427
37,1;37,2;37,3;37,4
#### Text ####
analysts said
##############
but, Comparison.Contrast
____Arg1____
5185..5286
37,0,0;37,0,1;37,0,2;37,0,3
#### Text ####
Also, the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
5292..5412
37,0,5
#### Text ####
the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
5429
38
____Arg1____
5185..5427
37
#### Text ####
Also, the company's hair-growing drug, Rogaine, is selling well -- at about $125 million for the year, but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising, analysts said
##############
____Arg2____
5429..5473
38
#### Text ####
In Kalamazoo, Mich., Upjohn declined comment
##############
________________________________________________________
